Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

被引:16
|
作者
Milman, Garry [1 ]
Bergamaschi, Mateus M. [1 ]
Lee, Dayong [1 ]
Mendu, Damodara R. [1 ]
Barnes, Allan J. [1 ]
Vandrey, Ryan [2 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Chem & Drug Metab Sect, Intramural Res Program, Biomed Res Ctr,NIH, Baltimore, MD 21224 USA
[2] Johns Hopkins Bayview Med Ctr, Behav Pharmacol Res Unit, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
dronabinol; plasma; cannabinoids; smoking; oral administration; ORAL THC; DELTA-9-TETRAHYDROCANNABINOL CONCENTRATIONS; TOBACCO WITHDRAWAL; MARIJUANA; SMOKING; BLOOD; DELTA(9)-TETRAHYDROCANNABINOL; ABSORPTION; THCCOOH; IMPACT;
D O I
10.1097/FTD.0b013e3182a5c446
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Recently, high-dose oral synthetic delta-9-tetrahydrocannabinol (THC) was shown to alleviate cannabis withdrawal symptoms. The present data describe cannabinoid pharmacokinetics in chronic, daily cannabis smokers who received high-dose oral THC pharmacotherapy and later a smoked cannabis challenge.Methods:Eleven daily cannabis smokers received 0, 30, 60, or 120 mg/d THC for four 5-day medication sessions, each separated by 9 days of ad libitum cannabis smoking. On the fifth day, participants were challenged with smoking one 5.9% THC cigarette. Plasma collected on the first and fifth days was quantified by two-dimensional gas chromatography mass spectrometer for THC, 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Linear ranges (ng/mL) were 0.5-100 for THC, 1-50 for 11-OH-THC, and 0.5-200 for THCCOOH.Results:During placebo dosing, THC, 11-OH-THC, and THCCOOH concentrations consistently decreased, whereas all cannabinoids increased dose dependently during active dronabinol administration. THC increase over time was not significant after any dose, 11-OH-THC increased significantly during the 60- and 120-mg/d doses, and THCCOOH increased significantly only during the 120-mg/d dose. THC, 11-OH-THC, and THCCOOH concentrations peaked within 0.25 hours after cannabis smoking, except after 120 mg/d THC when THCCOOH peaked 0.5 hours before smoking.Conclusions:The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases. During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression. THC concentrations after cannabis smoking were only distinguishable from oral THC doses for 1 hour, too short a period to feasibly identify cannabis relapse. THCCOOH/THC ratios were higher 14 hours after overnight oral dronabinol abstinence but cannot distinguish oral THC dosing from the smoked cannabis intake.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 50 条
  • [1] Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
    Koch, Christopher D.
    Xu, Liang
    Curtis, Susanna A.
    Roberts, John D.
    Bunch, Dustin R.
    El-Khoury, Joe M.
    CLINICA CHIMICA ACTA, 2020, 510 : 515 - 521
  • [2] Use of dronabinol for cannabis dependence: Two case reports and review
    Levin, Frances R.
    Kleber, Herbert D.
    AMERICAN JOURNAL ON ADDICTIONS, 2008, 17 (02): : 161 - 164
  • [3] Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette
    Marsot, A.
    Audebert, C.
    Attolini, L.
    Lacarelle, B.
    Micallef, J.
    Blin, O.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2016, 19 (03): : 411 - 422
  • [4] Pharmacotherapy for Cannabis Dependence How Close Are We?
    Vandrey, Ryan
    Haney, Margaret
    CNS DRUGS, 2009, 23 (07) : 543 - 553
  • [5] Cannabinoid syndrome in cannabis dependence: a case report
    Pichilingue Reto, C.
    Jose Rojo, A. M.
    Carrillo Reche, M. B.
    EUROPEAN PSYCHIATRY, 2024, 67 : S398 - S398
  • [6] Cannabinoid concentrations in hair from documented cannabis users
    Huestis, Marilyn A.
    Gustafson, Richard A.
    Moolchan, Eric T.
    Barnes, Allan
    Bourland, James A.
    Sweeney, Stacy A.
    Hayes, Eugene F.
    Carpenter, Patrick M.
    Smith, Michael L.
    FORENSIC SCIENCE INTERNATIONAL, 2007, 169 (2-3) : 129 - 136
  • [7] Urinary Cannabis Metabolite Concentrations in Cannabinoid Hyperemesis Syndrome
    Cordova, Jonathan
    Biank, Vincent
    Black, Elizabeth
    Leikin, Jerrold
    CLINICAL TOXICOLOGY, 2019, 57 (10) : 994 - 995
  • [8] Psychosexual dysfunction in male patients with cannabis dependence and synthetic cannabinoid dependence
    Asal, Abdelrahman A.
    Ayoub, Doaa R.
    Mazen, Mohamed E.
    El Makawi, Shirin M.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2025, 60 (01): : 44 - 56
  • [9] Hair cannabinoid concentrations in emergency patients with cannabis hyperemesis syndrome
    Albert, Khala
    Sivilotti, Marco L. A.
    Gareri, Joey
    Day, Andrew
    Ruberto, Aaron J.
    Hookey, Lawrence C.
    CANADIAN JOURNAL OF EMERGENCY MEDICINE, 2019, 21 (04) : 477 - 481
  • [10] Cannabinoid concentrations in Canada's regulated medical cannabis industry
    Mammen, George
    de Freitas, Lauren
    Rehm, Juergen
    Rueda, Sergio
    ADDICTION, 2017, 112 (04) : 730 - 732